WHAT IS CLAIMED IS:

1		1.	A method for preventing or treating an autoimmune disease in a	
2	subject, the m	ethod o	comprising the step of administering to the subject a therapeutically	
3	effective amount of an Activity Dependent Neurotrophic Factor (ADNF) polypeptide,			
4	wherein the ADNF polypeptide is a member selected from the group consisting of:			
5	(a) an ADNF I polypeptide comprising an active core site having the following			
6	amino acid sequence:			
7	Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1);			
8	(b) an ADNF III polypeptide comprising an active core site having the			
9	following amino acid sequence:			
10	Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2); and			
11	(c) a mixture of the ADNF I polypeptide of part (a) and the ADNF III			
12	polypeptide of part (b).			
1		2.	The method of claim 1, wherein the ADNF polypeptide is a member	
2	selected from		oup consisting of a full length ADNF I polypeptide, a full length ADNF	
3	III polypeptide, and a mixture of a full length ADNF I polypeptide and a full length ADNF			
4	III polypeptide			
	1 21 1			
1		3.	The method of claim 1, wherein the ADNF polypeptide is an ADNF I	
2	polypeptide.			
1		4.	The method of claim 3, wherein the active core site of the ADNF I	
2	polypeptide comprises at least one D-amino acid.		· · · · · · · · · · · · · · · · · · ·	
	1 71 1	•		
1		5.	The method of claim 3, wherein the active core site of the ADNF I	
2 .	polypeptide co	ompris	es all D-amino acids.	
1		6.	The method of claim 3, wherein the ADNF I polypeptide is Ser-Ala-	
2	Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1).			
	•			
1		7.	The method of claim 3, wherein the ADNF I polypeptide is selected	
2	from the group consisting of:			
3	Val-Leu-Gly-Gly-Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:14);			

- Val-Glu-Glu-Gly-Ile-Val-Leu-Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala

 (SEQ ID NO:15);

 Leu-Gly-Gly-Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:16);

 Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:17);

 Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:18);
- 9 Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:19); and
- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1).
- 1 8. The method of claim 3, wherein the ADNF I polypeptide comprises up 2 to about 20 amino acids at at least one of the N-terminus and the C-terminus of the active 3 core site.
- 1 9. The method of claim 1, wherein the ADNF polypeptide is an ADNF III 2 polypeptide.
- 1 10. The method of claim 9, wherein the ADNF polypeptide is a full length 2 ADNF III polypeptide.
- 1 11. The method of claim 9, wherein the ADNF III polypeptide is Asn-Ala-2 Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:1).
- 1 12. The method of claim 9, wherein the active core site of the ADNF III 2 polypeptide comprises at least one D-amino acid.
- 1 13. The method of claim 9, wherein the active core site of the ADNF III 2 polypeptide comprises all D-amino acids.
- 1 14. The method of claim 9, wherein the ADNF III polypeptide is a 2 member selected from the group consisting of:
- 3 Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2);
- 4 Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ ID NO:3);
- 5 Leu-Gly-Leu-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ ID NO:4);
- 6 Ser-Val-Arg-Leu-Gly-Leu-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ
- 7 ID NO:5); and
- 8 Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:1).

1	15. The method of claim 9, wherein the ADNF III polypeptide comprises			
2	up to about 20 amino acids at at least one of the N-terminus and the C-terminus of the active			
3	core site.			
1	16. The method of claim 1, wherein at least one of the ADNF polypeptides			
2	is encoded by a nucleic acid that is administered to the subject.			
1	17. The method of claim 1, wherein an ADNF I polypeptide of part (a) and			
2	an ADNF III polypeptide of part (b) are administered to the subject.			
1	18. The method of claim 17, wherein either or both active core sites of the			
2	ADNF I polypeptide and the ADNF III polypeptide comprise at least one D-amino acid.			
1	19. The method of claim 17, wherein either or both active core sites of the			
2	ADNF I polypeptide and the ADNF III polypeptide comprise all D-amino acids.			
1	20. The method of claim 17, wherein the ADNF I polypeptide is Ser-Ala-			
2	Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1), and wherein the ADNF III polypeptide is			
3	Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2).			
1	21. The method of claim 17, wherein the ADNF I polypeptide is a member			
2	selected from the group consisting of:			
3	Val-Leu-Gly-Gly-Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:14);			
4	Val-Glu-Glu-Gly-Ile-Val-Leu-Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala			
5	(SEQ ID NO:15);			
6	Leu-Gly-Gly-Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:16);			
7	Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:17);			
8	Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:18);			
9	Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:19); and			
10	Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1); and			
11	wherein the ADNF III polypeptide is selected from the group consisting of:			
12	Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:20);			
13	Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ ID NO:21);			
14	Leu-Gly-Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ ID NO:22);			

.15	Ser-Val-Arg-Leu-Gly-Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ		
16	ID NO:23); and		
17	7 Asn-Ala-Pro-Val-Ser-Ile-	Pro-Gln (SEQ ID NO:2).	
1	The metho	d of claim 17, wherein the ADNF I polypeptide comprises	
2	up to about 20 amino acids at at least one of the N-terminus and the C-terminus of the active		
3	core site of the ADNF I polypeptide, and wherein the ADNF III polypeptide comprises up to		
4	about 20 amino acids at at least one of the N-terminus and the C-terminus of the active core		
5	site of the ADNF III polypeptide.		
1	23. The metho	d of claim 1, wherein the subject has an autoimmune	
2	2 disease.		
1	24. The method	d of claim 1, wherein the ADNF polypeptide is administered	
2	to prevent an autoimmune disease	.	
1	The method	d of claim 1, wherein the autoimmune disease is selected	
1 2		d of claim 1, wherein the autoimmune disease is selected iple sclerosis, myasthenia gravis, Guillan-Barre syndrome	
	2 from the group consisting of mult	·	
2	from the group consisting of mult (antiphospholipid syndrome), sys	iple sclerosis, myasthenia gravis, Guillan-Barre syndrome	
2	from the group consisting of mult (antiphospholipid syndrome), sys syndrome, rheumatoid arthritis, H	iple sclerosis, myasthenia gravis, Guillan-Barre syndrome temic lupus erytromatosis, Behcet's syndrome, Sjogrens	
2 3 4	from the group consisting of mult (antiphospholipid syndrome), sys syndrome, rheumatoid arthritis, H cirrhosis, mixed connective tissue	iple sclerosis, myasthenia gravis, Guillan-Barre syndrome temic lupus erytromatosis, Behcet's syndrome, Sjogrens (ashimoto's disease/hypothyroiditis, primary biliary	
2 3 4 5	from the group consisting of mult (antiphospholipid syndrome), sys syndrome, rheumatoid arthritis, E cirrhosis, mixed connective tissue disease/hyperthyroiditis, sclerode	iple sclerosis, myasthenia gravis, Guillan-Barre syndrome temic lupus erytromatosis, Behcet's syndrome, Sjogrens (ashimoto's disease/hypothyroiditis, primary biliary e disease, chronic active hepatitis, Graves'	
2 3 4 5 6	from the group consisting of multiples (antiphospholipid syndrome), sys syndrome, rheumatoid arthritis, E cirrhosis, mixed connective tissue disease/hyperthyroiditis, sclerode neuropathy and septic shock.	iple sclerosis, myasthenia gravis, Guillan-Barre syndrome temic lupus erytromatosis, Behcet's syndrome, Sjogrens (ashimoto's disease/hypothyroiditis, primary biliary e disease, chronic active hepatitis, Graves'	
2 3 4 5 6 7	from the group consisting of multiples (antiphospholipid syndrome), sys syndrome, rheumatoid arthritis, E cirrhosis, mixed connective tissue disease/hyperthyroiditis, sclerode neuropathy and septic shock. 26. The method	iple sclerosis, myasthenia gravis, Guillan-Barre syndrome temic lupus erytromatosis, Behcet's syndrome, Sjogrens (ashimoto's disease/hypothyroiditis, primary biliary disease, chronic active hepatitis, Graves' rma, chronic idiopathic thrombocytopenic purpura, diabetic	
2 3 4 5 6 7	from the group consisting of multiples (antiphospholipid syndrome), sys syndrome, rheumatoid arthritis, E cirrhosis, mixed connective tissue disease/hyperthyroiditis, sclerode neuropathy and septic shock. 26. The method intranasally.	iple sclerosis, myasthenia gravis, Guillan-Barre syndrome temic lupus erytromatosis, Behcet's syndrome, Sjogrens (ashimoto's disease/hypothyroiditis, primary biliary disease, chronic active hepatitis, Graves' rma, chronic idiopathic thrombocytopenic purpura, diabetic	
2 3 4 5 6 7 1 2	from the group consisting of multiples (antiphospholipid syndrome), sys syndrome, rheumatoid arthritis, He cirrhosis, mixed connective tissued disease/hyperthyroiditis, sclerode neuropathy and septic shock. 26. The method intranasally.	iple sclerosis, myasthenia gravis, Guillan-Barre syndrome temic lupus erytromatosis, Behcet's syndrome, Sjogrens (ashimoto's disease/hypothyroiditis, primary biliary disease, chronic active hepatitis, Graves' rma, chronic idiopathic thrombocytopenic purpura, diabetic d of claim 1, wherein the ADNF polypeptide is administered	